Results 121 to 130 of about 494,154 (252)

Multidistrict Outbreak of Marburg Virus Disease—Uganda, 2012 [PDF]

Journal of Infectious Diseases, 2015
In October 2012, a cluster of illnesses and deaths was reported in Uganda and was confirmed to be an outbreak of Marburg virus disease (MVD). Patients meeting the case criteria were interviewed using a standard investigation form, and blood specimens were tested for evidence of acute or recent Marburg virus infection by reverse transcription-polymerase
Barbara, Knust, Ilana J, Schafer, Joseph, Wamala, Luke, Nyakarahuka, Charles, Okot, Trevor, Shoemaker, Kimberly, Dodd, Aridth, Gibbons, Stephen, Balinandi, Alex, Tumusiime, Shelley, Campbell, Edmund, Newman, Estrella, Lasry, Hilde, DeClerck, Yap, Boum, Issa, Makumbi, Henry Kyobe, Bosa, Anthony, Mbonye, Jane Ruth, Aceng, Stuart T, Nichol, Ute, Ströher, Pierre E, Rollin   +21 more
openaire   +2 more sources

Plasma proteomic profiling and molecular clustering reveal immune‐defined prognostic subtypes in lung adenocarcinoma

International Journal of Cancer, Volume 158, Issue 4, Page 858-865, 15 February 2026.
What's new? Lung adenocarcinoma shows considerable heterogeneity in disease progression and therapeutic response. Here, the authors analyzed tumor samples through proteomic profiling and applied network‐based clustering. They identified two distinct patient groups with different demographic, clinical, and molecular characteristics.
Ujjwal Neogi, Anoop T. Ambikan, Kati Turkowski, Marc A. Schneider, Vanessa M. Beutgen, Johannes Graumann, Hauke Winter, Marek Bartkuhn, Werner Seeger, Soni S. Pullamsetti, Rajkumar Savai   +10 more
wiley   +1 more source

Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruse.

PLoS Pathogens
Viral haemorrhagic fevers (VHF) pose a significant threat to human health. In recent years, VHF outbreaks caused by Ebola, Marburg and Lassa viruses have caused substantial morbidity and mortality in West and Central Africa.
Amy Flaxman, Sarah Sebastian, Sofia Appelberg, Kuan M Cha, Marta Ulaszewska, Jyothi Purushotham, Ciaran Gilbride, Hannah Sharpe, Alexandra J Spencer, Sagida Bibi, Daniel Wright, Isabel Schmidt, Stuart Dowall, Linda Easterbrook, Stephen Findlay-Wilson, Sarah Gilbert, Ali Mirazimi, Teresa Lambe   +17 more
doaj   +1 more source

Lyophilisation of influenza, rabies and Marburg lentiviral pseudotype viruses for the development and distribution of a neutralisation-assay based diagnostic kit [PDF]

, 2014
Pseudotype viruses (PVs) are chimeric, replication-deficient virions that mimic wild-type virus entry mechanisms and can be safely employed in neutralisation assays, bypassing the need for high biosafety requirements and performing comparably to ...
Assar, Berge, Brauburger, Capecchi, Cliquet, Cox, Croyle, Demaison, Desvaux, Edward Wright, Fellowes, Gao, Higashikawa, Jackson, Kaku, Kishishita, Loi, Lowen, Mather, Molesti, Nigel J. Temperton, Noti, Papenburg, Pear, Scott, Scott, Shin, Simon D. Scott, Stoker, Stuart T. Mather, Temperton, Temperton, Terregino, To, Tong, Tyrrell, Wei, WHO, WHO, Wilschut, Wright, Wright, Wright, Yuen, Zufferey   +44 more
core   +3 more sources

A Phase 1 Randomized Study: Garadacimab Pharmacokinetics, Safety, and Tolerability After Administration via Autoinjector/Pre‐Filled Pen Versus Pre‐Filled Syringe in Healthy Participants

The Journal of Clinical Pharmacology, Volume 66, Issue 1, January 2026.
Abstract Garadacimab is a novel, fully human, anti‐activated factor XII monoclonal antibody approved for long‐term prophylaxis of patients with hereditary angioedema. This open‐label, parallel‐group, Phase 1, single‐center, bridging study in healthy adults (18–55 years of age) characterized the pharmacokinetics and safety of a single 200 mg ...
Fiona Glassman, John‐Philip Lawo, Mihai Alexandru Bica, Anthony Roberts, David Kormann, Ligia Chialda, Soeren Miethke, Iwona Dziadowiec, Stephen Caltabiano, Thomas Puchalski   +9 more
wiley   +1 more source

Containing the threat - don't forget Ebola [PDF]

, 2004
In 2000, Uganda experienced the largest outbreak of Ebola fever ever described.
Geisbert, Jonathan Cohen, Lamunu
core   +4 more sources

Chronic Hepatitis B Virus Infection Acquired Under Cytostatic Treatment in Childhood — Clinical, Virological and Immunological Long‐Term Follow‐Up

Journal of Viral Hepatitis, Volume 33, Issue 1, January 2026.
ABSTRACT Oncology patients receiving cytostatic therapy used to be at high risk of HBV infection when HBV screening measures were less reliable. Infections acquired under these conditions often persist, like those acquired perinatally or during early infancy.
Thomas Baumgarten, Felix Lehmann, Tina Senff, Heiko Slanina, Christian G. Schüttler, Andreas Walker, Wolfram H. Gerlich, Reinald Repp, Jörg Timm, Dieter Glebe, Markus Metzler   +10 more
wiley   +1 more source

Treatment of Hereditary Angioedema With Plasma‐Derived C1 Inhibitor: A Review

Clinical and Translational Allergy, Volume 15, Issue 12, December 2025.
ABSTRACT Hereditary angioedema (HAE) is clinically characterized by recurrent episodes of localized edema. HAE typically occurs due to a deficiency of functional C1 inhibitor (C1INH, HAE‐C1INH); in addition, several types of HAE with normal quantity and activity of C1INH (HAE‐nC1INH) have recently been classified, which occur due to different gene ...
Inmaculada Martinez‐Saguer, Ingo Pragst, Beverley Worrall, Konrad Bork   +3 more
wiley   +1 more source

Marburg Virus Disease: Pathophysiology, Diagnostic Challenges, and Global Health Preparedness Strategies [PDF]

Ann Glob Health
Background: Marburg virus disease (MVD) is a highly virulent viral hemorrhagic fever with reported case fatality rates of up to 90%. It is part of the same family as the Ebola virus (Filoviridae).
Francis D, Reddy S, Logaranjani A, Sai Karthikeyan S, Rathi M.   +4 more
europepmc   +2 more sources

Next‐Generation Proteolysis‐Targeting Chimeras in Precision Oncology: Multifunctional Designs, Emerging Modalities, and Translational Prospects in Targeted Protein Degradation

Drug Development Research, Volume 86, Issue 8, December 2025.
ABSTRACT Proteolysis‐targeting chimeras (PROTACs)‐mediated protein degradation has been recently developed as a game‐changing approach in oncology drug development. It represents a paradigm shift from traditional enzyme inhibition to selective protein degradation.
Mohamed S. Nafie, Mohamed K. Diab, Asmaa S. A. Yassen, Amany M. Elshamy, Mohamed R. El Tohamy, Haytham O. Tawfik, Sherif Ashraf Fahmy   +6 more
wiley   +1 more source